Evidence map›Paper›PMID 35371419›Full record

ArticleDermatology reports2022

Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report.

Anna Passarelli, Giovanna Galdo, Teresa Pellegrino, Giandomenico Roviello, Michele Aieta, Gabriella Aviello, Raffaele Conca

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anna PassarelliUnit of Medical Oncology, Department of Onco-Hematology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture (PZ).
Giovanna GaldoOncologic Dermatology Unit, Department of Onco-Hematology, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata (IRCCSCROB), Rionero in Vulture (PZ).
Teresa PellegrinoNuclear Medicine Department, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture (PZ).
Giandomenico RovielloDepartment of Health Sciences, University of Florence.
Michele AietaUnit of Medical Oncology, Department of Onco-Hematology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture (PZ).
Gabriella AvielloDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Raffaele ConcaUnit of Medical Oncology, Department of Onco-Hematology, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture (PZ).
Centro di Riferimento Oncologico della Basilicata · ITUniversity of Florence · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaposi's sarcoma (KS) is a rare inflammation- based vascular cancer involving the skin. The viral aetiology of KS is the Human Herpesvirus 8. KS may be frequently diagnosed in immunosuppressed kidneytransplanted patients, while is less common in patients with dialysis. It is known that various immunological abnormalities can lead to impaired immune status in uremic patients. It is noteworthy that despite the incidence of KS in patients with renal impairment, only few cases have reported efficacy and safety profile of KS targeting anti-cancer drugs in this kidney disease population. Herein, we report the first case of a symptomatic KS patient with renal disease in haemodialysis and focus on its therapeutic management. We also review the main data available from literature regarding the safety of KS therapy in dialysis patients.

Indexed as

Chronic renal impairmentHaemodialysisHuman herpesvirus 8Kaposi sarcomaPomalidomide

Identifiers

PMID35371419
PMCPMC8969873
OpenAlexW4225794719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.